<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02747927</url>
  </required_header>
  <id_info>
    <org_study_id>DEN-301</org_study_id>
    <secondary_id>U1111-1166-8401</secondary_id>
    <secondary_id>PHRR150522-001010</secondary_id>
    <secondary_id>2018-003979-34</secondary_id>
    <nct_id>NCT02747927</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children</brief_title>
  <acronym>TIDES</acronym>
  <official_title>Phase III, Double-Blind, Randomized, Placebo-Controlled Trial to Investigate the Efficacy, Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TDV) Administered Subcutaneously in Healthy Children Aged 4 - 16 Years Old</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the efficacy of 2 doses of Tetravalent Dengue&#xD;
      Vaccine Candidate (TDV) in preventing symptomatic dengue fever of any severity and due to any&#xD;
      of the four dengue virus serotypes in 4 to 16 year old participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The vaccine being tested in this study is Takeda's Tetravalent Dengue Vaccine Candidate&#xD;
      (TDV). TDV is being tested to protect people against dengue fever and to look at long-term&#xD;
      safety results. This study will look at the success rate of TDV in preventing dengue fever&#xD;
      (vaccine efficacy) and long-term side effects of the vaccine.&#xD;
&#xD;
      The study will be conducted in 5 parts. Part 1 will evaluate vaccine efficacy (VE) and will&#xD;
      last a minimum of 15 months. Part 2 will be for an additional 6 months to evaluate VE. Part 3&#xD;
      will evaluate long-term safety by following participants for side effects and will last an&#xD;
      additional 3 years. Part 4 will evaluate safety for 13 months post-booster vaccination. Part&#xD;
      5 will be the long-term safety follow-up for 1 year after completion of Part 4. Participants&#xD;
      may be enrolled into a dry-run to commence and test febrile surveillance methodology; this&#xD;
      dry-run part may be up to 10 months prior to receiving study injection, however, will not be&#xD;
      applicable to all trials sites or participants.&#xD;
&#xD;
      Approximately 20,100 participants will be enrolled into the study and randomly assigned (by&#xD;
      chance) to one of the two treatment groups-which will remain undisclosed to the participants&#xD;
      and study doctors during the study (unless there is an urgent medical need):&#xD;
&#xD;
        -  TDV 0.5 mL subcutaneous injection&#xD;
&#xD;
        -  Placebo (dummy inactive subcutaneous injection) - this is a solution that looks like the&#xD;
           study drug but has no active ingredient&#xD;
&#xD;
      All participants will receive a single injection of TDV or placebo on Day 1, Day 90.&#xD;
      Participation in a booster phase will be offered to approximately 10,500 participants to&#xD;
      receive (TDV or placebo) on Day 1b (Day 1 in booster phase). A subset of participants will be&#xD;
      asked to record any local symptoms at the injection site (Pain, Erythema and Swelling) in a&#xD;
      diary card for 7 days after each injection. The same subset of participants will also be&#xD;
      asked to record any systemic symptoms (child &lt;6 years: fever, irritability/fussiness,&#xD;
      drowsiness, loss of appetite and child ≥6 years: fever, headache, asthenia, malaise and&#xD;
      myalgia) in a diary card for 14 days after each injection.&#xD;
&#xD;
      This multi-center trial will be conducted worldwide. The overall time to participate in this&#xD;
      study is approximately 7 years excluding the dry-run. Participants will make multiple visits&#xD;
      to the clinic and will be contacted at least every week for the entire study duration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 7, 2016</start_date>
  <completion_date type="Anticipated">March 21, 2024</completion_date>
  <primary_completion_date type="Actual">July 11, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vaccine Efficacy (VE) of Two Doses of Tetravalent Dengue Vaccine Candidate (TDV) in Preventing Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype</measure>
    <time_frame>30 days post-second vaccination (Day 120) until the end of Part 1 (120 cases of dengue fever are confirmed and minimum duration of participant follow-up of 12 months post-second vaccination)</time_frame>
    <description>The Vaccine Efficacy is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific reverse transcriptase polymerase chain reaction (RT-PCR). The primary endpoint of vaccine efficacy was assessed using the number of confirmed dengue cases that occurred during Part 1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VE of Two Doses of TDV in Preventing Virologically-Confirmed Dengue Fever Induced by Each Dengue Serotype</measure>
    <time_frame>From 30 days post-second vaccination (Day 120) until the end of Part 2 (up to 21 months)</time_frame>
    <description>VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific reverse transcriptase polymerase chain reaction (RT-PCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VE of Two Doses of TDV in Preventing Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype in Participants Dengue Seronegative at Baseline</measure>
    <time_frame>From 30 days post-second vaccination (Day 120) until the end of Part 2 (up to 21 months)</time_frame>
    <description>VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific reverse transcriptase polymerase chain reaction (RT-PCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VE of Two Doses of TDV in Preventing Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype in Participants Dengue Seropositive at Baseline</measure>
    <time_frame>From 30 days post-second vaccination (Day 120) until the end of Part 2 (up to 21 months)</time_frame>
    <description>VE is defined as 1 - (λv/λC), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific reverse transcriptase polymerase chain reaction (RT-PCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VE of Two Doses of TDV in Preventing Hospitalization Due to Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype</measure>
    <time_frame>From 30 days post-second vaccination (Day 120) until the end of Part 2 (up to 21 months)</time_frame>
    <description>VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific reverse transcriptase polymerase chain reaction (RT-PCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VE of Two Doses of TDV in Preventing Virologically-Confirmed Severe Dengue Fever Induced by Any Dengue Serotype</measure>
    <time_frame>From 30 days post-second vaccination (Day 120) until the end of Part 2 (up to 21 months)</time_frame>
    <description>VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific reverse transcriptase polymerase chain reaction (RT-PCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Solicited Local Injection Site Adverse Events (AEs) by Severity in the Safety Subset</measure>
    <time_frame>Days 1 through 7 after each vaccination</time_frame>
    <description>Solicited local AEs at injection site are defined as pain, erythema and swelling that occurred within 7 days after each vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Solicited Systemic Adverse Events (AEs) by Severity in the Safety Subset</measure>
    <time_frame>Days 1 through 14 after each vaccination</time_frame>
    <description>Solicited systemic AEs in children (&lt; 6 years) are defined as fever, irritability/fussiness, drowsiness and loss of appetite that occurred within 14 days after each vaccination. Solicited systemic AEs in children (≥ 6 years) are defined as fever, headache, asthenia, malaise and myalgia that occurred within 14 days after each vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Solicited Systemic Adverse Events (AEs) in the Safety Subset</measure>
    <time_frame>Days 1 through 14 after each vaccination</time_frame>
    <description>Solicited systemic AEs in children (&lt; 6 years) are defined as fever, irritability/fussiness, drowsiness and loss of appetite that occurred within 14 days after each vaccination. Solicited systemic AEs in children (≥ 6 years) are defined as fever, headache, asthenia, malaise and myalgia that occurred within 14 days after each vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Any Unsolicited Adverse Events (AEs) in the Safety Subset</measure>
    <time_frame>Days 1 through 28 after each vaccination</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration. Unsolicited AEs are any AEs that are not solicited local or systemic AEs, as defined by this study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Serious Adverse Events (SAEs) During Parts 1 and 2</measure>
    <time_frame>From Day 1 until the end of Parts 1 and 2 (approximately 21 months)</time_frame>
    <description>A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Fatal SAEs and SAEs Related to Study Drug During the First and Second Half of Part 3</measure>
    <time_frame>First and Second half (18 months each) of Part 3 (up to 3 years, beginning at Month 22)</time_frame>
    <description>A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Seropositive Response for Each of the Four Dengue Serotypes in the Immunogenicity Subset</measure>
    <time_frame>Prevaccination on Day 1, post-first vaccination on Month 1, pre-vaccination on Month 3; post-second vaccination at Months 4, 9 and 15, and then annually (up to 3 years)</time_frame>
    <description>Seropositive response is defined as a reciprocal neutralizing titer ≥ 10. The four DENV serotypes are DEN-1, DEN-2, DEN-3 and DEN-4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Seropositive Response for Multiple Dengue Serotypes in the Immunogenicity Subset</measure>
    <time_frame>Prevaccination on Day 1, post-first vaccination on Month 1, pre-vaccination on Month 3; post-second vaccination at Months 4, 9 and 15, and then annually (up to 3 years)</time_frame>
    <description>Seropositive response is defined as a reciprocal neutralizing titer ≥ 10. The four DENV serotypes are DEN-1, DEN-2, DEN-3 and DEN-4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the Four Dengue Serotypes in the Immunogenicity Subset</measure>
    <time_frame>Prevaccination on Day 1, post-first vaccination on Month 1, pre-vaccination on Month 3; post-second vaccination at Months 4, 9 and 15, and then annually (up to 3 years)</time_frame>
    <description>GMTs of neutralizing antibodies will be measured via microneutralization test 50% (MNT50). The four DENV serotypes are DEN-1, DEN-2, DEN-3 and DEN-4.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20099</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo-matching TDV, 0.5mL, subcutaneous (SC) injection on Day 1 (Month 0) and Day 90 (Month 3). Participants eligible for Booster Phase received placebo matching TDV, SC injection, based on the randomization on Day 1 (Month 0).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tetravalent Dengue Vaccine (TDV) 0.5 mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TDV, 0.5mL, subcutaneous (SC) injection on Day 1 (Month 0) and Day 90 (Month 3). Participants eligible for Booster Phase received TDV, SC injection, based on the randomization on Day 1 (Month 0).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>TDV placebo-matching SC injection.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tetravalent Dengue Vaccine (TDV)</intervention_name>
    <description>TDV SC injection.</description>
    <arm_group_label>Tetravalent Dengue Vaccine (TDV) 0.5 mL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Is aged 4 to 16 years, inclusive, at the time of randomization.&#xD;
&#xD;
          2. Is in good health at the time of entry into the trial as determined by medical&#xD;
             history, physical examination (including vital signs) and clinical judgment of the&#xD;
             Investigator.&#xD;
&#xD;
          3. The participant and/or the participant's parent/guardian signs and dates an&#xD;
             assent/written informed consent form where applicable, and any required privacy&#xD;
             authorization prior to the initiation of any trial procedures, after the nature of the&#xD;
             trial has been explained according to local regulatory requirements.&#xD;
&#xD;
          4. Can comply with trial procedures and are available for the duration of follow-up.&#xD;
&#xD;
        Inclusion criteria for Booster Phase:&#xD;
&#xD;
          1. Is included in the per-protocol set (PPS) of the trial.&#xD;
&#xD;
          2. Was aged 4 to 11 years at the time of randomization in the study (Day 1 [Month 0]).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has febrile illness (temperature ≥38°C) or moderate or severe acute illness or&#xD;
             infection at the time of randomization.&#xD;
&#xD;
          2. Has history of or any illness that, in the opinion of the Investigator, might&#xD;
             interfere with the results of the trial or pose an additional risk to the participant&#xD;
             due to participation in the trial.&#xD;
&#xD;
          3. Has received any other vaccine within 14 days (for inactivated vaccines) or 28 days&#xD;
             (for live vaccines) prior to Day 1 (Month 0) or planning to receive any vaccine within&#xD;
             28 days after Day 1 (Month 0).&#xD;
&#xD;
          4. Has participated in any clinical trial with another investigational product 30 days&#xD;
             prior to Day 1 (Month 0) or intent to participate in another clinical trial at any&#xD;
             time during the conduct of this trial.&#xD;
&#xD;
          5. Has previously participated in any clinical trial of a dengue candidate vaccine, or&#xD;
             previous receipt of a dengue vaccine.&#xD;
&#xD;
          6. Is first degree relative of individuals involved in trial conduct.&#xD;
&#xD;
          7. Females of childbearing potential who are sexually active, and who have not used any&#xD;
             of the acceptable contraceptive methods for at least 2 months prior to Day 1 (Month&#xD;
             0).&#xD;
&#xD;
          8. Females of childbearing potential who are sexually active, and who refuse to use an&#xD;
             acceptable contraceptive method up to 6 weeks post-second vaccination.&#xD;
&#xD;
          9. Deprived of freedom by administrative or court order, or in an emergency setting, or&#xD;
             hospitalized involuntarily.&#xD;
&#xD;
         10. Current alcohol abuse or drug addiction that may interfere with the participant's&#xD;
             ability to comply with trial procedures.&#xD;
&#xD;
         11. Identified as an employee of the Investigator or trial center, with direct involvement&#xD;
             in the proposed trial or other trials under the direction of that Investigator or&#xD;
             trial center.&#xD;
&#xD;
        Exclusion criteria for Booster Phase:&#xD;
&#xD;
          1. Receipt of any other vaccine within 14 days (for inactivated vaccines) or 28 days (for&#xD;
             live vaccines) prior to Day 1b (Month 0b), or planning to receive any vaccine within&#xD;
             28 days after Day 1b (Month 0b).&#xD;
&#xD;
          2. Participation in any clinical trial with another investigational product at any time&#xD;
             during participation in this trial or intent to participate in another clinical trial&#xD;
             at any time during the conduct of the booster phase of this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Associacao Obras Sociais Irma Dulce Hospital Santo Antonio</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>40415-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidade Federal Do Espirito Santo Hospital Universitario Cassiano Antonio de Moraes HUCAM</name>
      <address>
        <city>Vitoria</city>
        <state>Espirito Santo</state>
        <zip>29040-091</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de Mato Grosso do Sul</name>
      <address>
        <city>Campo Grande</city>
        <state>Mato Grosso Do Sul</state>
        <zip>79070-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudos e Pesquisa em Molestias Infecciosas LTDA (CPCLIN)</name>
      <address>
        <city>Cidade Alta</city>
        <state>Natal - RN</state>
        <zip>59025-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Atencion e Investigacion Medica S.A - CAIMED - Aguazul - PPDS-PV</name>
      <address>
        <city>Aguazul</city>
        <state>Casanare</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Atencion e Investigacion Medica S.A - CAIMED - Yopal - PPDS-PV</name>
      <address>
        <city>Yopal</city>
        <state>Casanare</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Atencion e Investigacion Medica S.A. - CAIMED - Acacias - PPDS-PV</name>
      <address>
        <city>Acacias</city>
        <state>Meta</state>
        <zip>507001</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudios em Infectologia Pediatrica SAS (CEIP S.A.S)</name>
      <address>
        <city>Cali</city>
        <state>San Fernando</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Maternidad Nuestra Senora de Altagracia</name>
      <address>
        <city>Santo Domingo</city>
        <state>Distrito Nacional Santo Domingo</state>
        <zip>10204</zip>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caimed Dominicana S.A.S - PPDS-PV</name>
      <address>
        <city>Santo Domingo</city>
        <state>Distrito Nacional Santo Domingo</state>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidad Nacional Autonoma de Nicaragua</name>
      <address>
        <city>Leon</city>
        <country>Nicaragua</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro De Vacunacion Internacional, S.A. (Cevaxin)</name>
      <address>
        <city>Ciudad de Panama</city>
        <zip>10662</zip>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro De Vacunacion Internacional, S.A. (Cevaxin) Sede 24 de Diciembre</name>
      <address>
        <city>Panama</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro De Vacunacion Internacional, S.A. (Cevaxin) Sede Plaza Carolina</name>
      <address>
        <city>Panama</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro De Vacunacion Internacional, S.A.(Cevaxin) - La Chorrera</name>
      <address>
        <city>Panama</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dela Salle Health Sciences Institute</name>
      <address>
        <city>Dasmarinas</city>
        <state>Cavite</state>
        <zip>4114</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philippines-AFRIMS Virology Research Unit</name>
      <address>
        <city>Cebu City</city>
        <state>Cebu</state>
        <zip>6000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of the Philippine Manila</name>
      <address>
        <city>Ermita</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Las Pinas Health Center A</name>
      <address>
        <city>Las Pinas</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Las Pinas Health Center D</name>
      <address>
        <city>Las Pinas</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute for Tropical Medicine</name>
      <address>
        <city>Muntinlupa</city>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lady Ridgeway Hospital for Children</name>
      <address>
        <city>Colombo</city>
        <zip>00800</zip>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colombo South Teaching Hospital</name>
      <address>
        <city>Dehiwala</city>
        <zip>10250</zip>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Negombo General Hospital</name>
      <address>
        <city>Negombo</city>
        <zip>11500</zip>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colombo North Teaching Hospital</name>
      <address>
        <city>Ragama</city>
        <zip>11010</zip>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hospital for Tropical Diseases</name>
      <address>
        <city>Bangkok</city>
        <state>Krung Thep Maha Nakhon</state>
        <zip>10270</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phramongkutklao Hospital</name>
      <address>
        <city>Bangkok</city>
        <state>Krung Thep Maha Nakhon</state>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Srinagarind Hospital</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>Dominican Republic</country>
    <country>Nicaragua</country>
    <country>Panama</country>
    <country>Philippines</country>
    <country>Sri Lanka</country>
    <country>Thailand</country>
  </location_countries>
  <removed_countries>
    <country>Peru</country>
    <country>Vietnam</country>
  </removed_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 14, 2016</study_first_submitted>
  <study_first_submitted_qc>April 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2016</study_first_posted>
  <results_first_submitted>July 23, 2021</results_first_submitted>
  <results_first_submitted_qc>July 23, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 18, 2021</results_first_posted>
  <disposition_first_submitted>July 25, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>July 25, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 2, 2019</disposition_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dengue</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol: Redacted Protocol Part 1</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 20, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT02747927/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Redacted Protocol Part 2</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 20, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT02747927/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Redacted Protocol Part 3</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 20, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT02747927/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 24, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT02747927/SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 26 investigative sites in the Philippines, Sri Lanka, Thailand, Brazil, Colombia, Dominican Republic, Nicaragua, Panama from 07 September 2016 to data cut-off date: 11 July 2018. The study is ongoing.</recruitment_details>
      <pre_assignment_details>Healthy children received TDV or placebo along with booster vaccination in this study. The study was conducted in different Parts. Data is reported only up to Part 1 and primary outcome measure analysis up to 11 July 2018.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo (Part 1)</title>
          <description>Placebo-matching TDV, 0.5mL, subcutaneous (SC) injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study.</description>
        </group>
        <group group_id="P2">
          <title>Tetravalent Dengue Vaccine (TDV) 0.5 mL (Part 1)</title>
          <description>TDV, 0.5mL, subcutaneous (SC) injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6698"/>
                <participants group_id="P2" count="13401"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated: Safety Set</title>
              <participants_list>
                <participants group_id="P1" count="6687"/>
                <participants group_id="P2" count="13380"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6477"/>
                <participants group_id="P2" count="12943"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="221"/>
                <participants group_id="P2" count="458"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Participant and/or Participants Parent/Guardian</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
                <participants group_id="P2" count="304"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not Specified</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Per protocol Set included all participants in the Full analysis set (FAS) who have no major protocol violations. FAS included all randomized participants who received at least 1 dose of the trial vaccines.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo (Part 1)</title>
          <description>Placebo-matching TDV, 0.5mL, subcutaneous (SC) injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study.</description>
        </group>
        <group group_id="B2">
          <title>Tetravalent Dengue Vaccine (TDV) 0.5 mL (Part 1)</title>
          <description>TDV, 0.5mL, subcutaneous (SC) injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6317"/>
            <count group_id="B2" value="12704"/>
            <count group_id="B3" value="19021"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6317"/>
                    <count group_id="B2" value="12704"/>
                    <count group_id="B3" value="19021"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.6" spread="3.34"/>
                    <measurement group_id="B2" value="9.6" spread="3.35"/>
                    <measurement group_id="B3" value="9.6" spread="3.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6317"/>
                    <count group_id="B2" value="12704"/>
                    <count group_id="B3" value="19021"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3098"/>
                    <measurement group_id="B2" value="6314"/>
                    <measurement group_id="B3" value="9412"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3219"/>
                    <measurement group_id="B2" value="6390"/>
                    <measurement group_id="B3" value="9609"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6317"/>
                    <count group_id="B2" value="12704"/>
                    <count group_id="B3" value="19021"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2378"/>
                    <measurement group_id="B2" value="4819"/>
                    <measurement group_id="B3" value="7197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6317"/>
                    <count group_id="B2" value="12704"/>
                    <count group_id="B3" value="19021"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2934"/>
                    <measurement group_id="B2" value="5888"/>
                    <measurement group_id="B3" value="8822"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6317"/>
                    <count group_id="B2" value="12704"/>
                    <count group_id="B3" value="19021"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="706"/>
                    <measurement group_id="B2" value="1351"/>
                    <measurement group_id="B3" value="2057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6317"/>
                    <count group_id="B2" value="12704"/>
                    <count group_id="B3" value="19021"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6317"/>
                    <count group_id="B2" value="12704"/>
                    <count group_id="B3" value="19021"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="284"/>
                    <measurement group_id="B3" value="415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race or Unknown</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6317"/>
                    <count group_id="B2" value="12704"/>
                    <count group_id="B3" value="19021"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167"/>
                    <measurement group_id="B2" value="360"/>
                    <measurement group_id="B3" value="527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6317"/>
                    <count group_id="B2" value="12704"/>
                    <count group_id="B3" value="19021"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="504"/>
                    <measurement group_id="B2" value="1091"/>
                    <measurement group_id="B3" value="1595"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colombia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6317"/>
                    <count group_id="B2" value="12704"/>
                    <count group_id="B3" value="19021"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1155"/>
                    <measurement group_id="B2" value="2268"/>
                    <measurement group_id="B3" value="3423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dominican Republic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6317"/>
                    <count group_id="B2" value="12704"/>
                    <count group_id="B3" value="19021"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="533"/>
                    <measurement group_id="B2" value="1007"/>
                    <measurement group_id="B3" value="1540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nicaragua</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6317"/>
                    <count group_id="B2" value="12704"/>
                    <count group_id="B3" value="19021"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="239"/>
                    <measurement group_id="B2" value="512"/>
                    <measurement group_id="B3" value="751"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Panama</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6317"/>
                    <count group_id="B2" value="12704"/>
                    <count group_id="B3" value="19021"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="944"/>
                    <measurement group_id="B2" value="1930"/>
                    <measurement group_id="B3" value="2874"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Philippines</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6317"/>
                    <count group_id="B2" value="12704"/>
                    <count group_id="B3" value="19021"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1306"/>
                    <measurement group_id="B2" value="2554"/>
                    <measurement group_id="B3" value="3860"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sri Lanka</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6317"/>
                    <count group_id="B2" value="12704"/>
                    <count group_id="B3" value="19021"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="683"/>
                    <measurement group_id="B2" value="1368"/>
                    <measurement group_id="B3" value="2051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thailand</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6317"/>
                    <count group_id="B2" value="12704"/>
                    <count group_id="B3" value="19021"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="953"/>
                    <measurement group_id="B2" value="1974"/>
                    <measurement group_id="B3" value="2927"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <population>Number analyzed is number of participants with data available for height at Baseline.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6317"/>
                    <count group_id="B2" value="12701"/>
                    <count group_id="B3" value="19018"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="134.89" spread="18.978"/>
                    <measurement group_id="B2" value="134.85" spread="19.152"/>
                    <measurement group_id="B3" value="134.86" spread="19.094"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <population>Number analyzed is number of participants with data available for weight at Baseline.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6317"/>
                    <count group_id="B2" value="12697"/>
                    <count group_id="B3" value="19014"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.77" spread="14.506"/>
                    <measurement group_id="B2" value="33.98" spread="14.951"/>
                    <measurement group_id="B3" value="33.91" spread="14.805"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>BMI=weight (kg)/[height (m)^2].</description>
          <population>Number analyzed is number of participants with data available for BMI at Baseline.</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6317"/>
                    <count group_id="B2" value="12696"/>
                    <count group_id="B3" value="19013"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.67" spread="3.644"/>
                    <measurement group_id="B2" value="17.76" spread="3.831"/>
                    <measurement group_id="B3" value="17.73" spread="3.770"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Vaccine Efficacy (VE) of Two Doses of Tetravalent Dengue Vaccine Candidate (TDV) in Preventing Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype</title>
        <description>The Vaccine Efficacy is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific reverse transcriptase polymerase chain reaction (RT-PCR). The primary endpoint of vaccine efficacy was assessed using the number of confirmed dengue cases that occurred during Part 1.</description>
        <time_frame>30 days post-second vaccination (Day 120) until the end of Part 1 (120 cases of dengue fever are confirmed and minimum duration of participant follow-up of 12 months post-second vaccination)</time_frame>
        <population>Per protocol Set included include all participants in the Full analysis set (FAS) who have no major protocol violations. FAS included all randomized participants who received at least 1 dose of the trial vaccines.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Part 1)</title>
            <description>Placebo-matching TDV, 0.5mL, subcutaneous (SC) injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Tetravalent Dengue Vaccine (TDV) 0.5 mL (Part 1)</title>
            <description>TDV, 0.5mL, subcutaneous (SC) injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Vaccine Efficacy (VE) of Two Doses of Tetravalent Dengue Vaccine Candidate (TDV) in Preventing Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype</title>
          <description>The Vaccine Efficacy is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific reverse transcriptase polymerase chain reaction (RT-PCR). The primary endpoint of vaccine efficacy was assessed using the number of confirmed dengue cases that occurred during Part 1.</description>
          <population>Per protocol Set included include all participants in the Full analysis set (FAS) who have no major protocol violations. FAS included all randomized participants who received at least 1 dose of the trial vaccines.</population>
          <units>number of cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6317"/>
                <count group_id="O2" value="12704"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Assuming true VE of 60% and, virologically confirmed cases of dengue fever induced by any dengue serotype occurring from 30 days post 2nd vaccination (Day 120) until end of Part 1 would provide at least 90% power to rule out vaccine effect of ≤25%.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Statistical significance was concluded if the lower bound of the 95% CI for the VE was above 25%. Since the hypotheses was tested in a confirmatory manner at a 2-sided significance level of 5%, the calculated p-value was compared with 0.025.</p_value_desc>
            <method>Cox Proportional Hazard Model</method>
            <method_desc>VE and 95% CIs was estimated from Cox proportional hazard model with investigational product as a factor, adjusted for age, and stratified by region.</method_desc>
            <param_type>Vaccine Efficacy (VE)</param_type>
            <param_value>80.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>73.3</ci_lower_limit>
            <ci_upper_limit>85.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VE of Two Doses of TDV in Preventing Virologically-Confirmed Dengue Fever Induced by Each Dengue Serotype</title>
        <description>VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific reverse transcriptase polymerase chain reaction (RT-PCR).</description>
        <time_frame>From 30 days post-second vaccination (Day 120) until the end of Part 2 (up to 21 months)</time_frame>
        <posting_date>03/2025</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VE of Two Doses of TDV in Preventing Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype in Participants Dengue Seronegative at Baseline</title>
        <description>VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific reverse transcriptase polymerase chain reaction (RT-PCR).</description>
        <time_frame>From 30 days post-second vaccination (Day 120) until the end of Part 2 (up to 21 months)</time_frame>
        <posting_date>03/2025</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VE of Two Doses of TDV in Preventing Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype in Participants Dengue Seropositive at Baseline</title>
        <description>VE is defined as 1 - (λv/λC), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific reverse transcriptase polymerase chain reaction (RT-PCR).</description>
        <time_frame>From 30 days post-second vaccination (Day 120) until the end of Part 2 (up to 21 months)</time_frame>
        <posting_date>03/2025</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VE of Two Doses of TDV in Preventing Hospitalization Due to Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype</title>
        <description>VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific reverse transcriptase polymerase chain reaction (RT-PCR).</description>
        <time_frame>From 30 days post-second vaccination (Day 120) until the end of Part 2 (up to 21 months)</time_frame>
        <posting_date>03/2025</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VE of Two Doses of TDV in Preventing Virologically-Confirmed Severe Dengue Fever Induced by Any Dengue Serotype</title>
        <description>VE is defined as 1 - (λv/λc), where λv and λc denote the hazard rates for the TDV and placebo arms, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature ≥38°C on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific reverse transcriptase polymerase chain reaction (RT-PCR).</description>
        <time_frame>From 30 days post-second vaccination (Day 120) until the end of Part 2 (up to 21 months)</time_frame>
        <posting_date>03/2025</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Solicited Local Injection Site Adverse Events (AEs) by Severity in the Safety Subset</title>
        <description>Solicited local AEs at injection site are defined as pain, erythema and swelling that occurred within 7 days after each vaccination.</description>
        <time_frame>Days 1 through 7 after each vaccination</time_frame>
        <posting_date>03/2025</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Solicited Systemic Adverse Events (AEs) by Severity in the Safety Subset</title>
        <description>Solicited systemic AEs in children (&lt; 6 years) are defined as fever, irritability/fussiness, drowsiness and loss of appetite that occurred within 14 days after each vaccination. Solicited systemic AEs in children (≥ 6 years) are defined as fever, headache, asthenia, malaise and myalgia that occurred within 14 days after each vaccination.</description>
        <time_frame>Days 1 through 14 after each vaccination</time_frame>
        <posting_date>03/2025</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Solicited Systemic Adverse Events (AEs) in the Safety Subset</title>
        <description>Solicited systemic AEs in children (&lt; 6 years) are defined as fever, irritability/fussiness, drowsiness and loss of appetite that occurred within 14 days after each vaccination. Solicited systemic AEs in children (≥ 6 years) are defined as fever, headache, asthenia, malaise and myalgia that occurred within 14 days after each vaccination.</description>
        <time_frame>Days 1 through 14 after each vaccination</time_frame>
        <posting_date>03/2025</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Any Unsolicited Adverse Events (AEs) in the Safety Subset</title>
        <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration. Unsolicited AEs are any AEs that are not solicited local or systemic AEs, as defined by this study.</description>
        <time_frame>Days 1 through 28 after each vaccination</time_frame>
        <posting_date>03/2025</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Serious Adverse Events (SAEs) During Parts 1 and 2</title>
        <description>A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.</description>
        <time_frame>From Day 1 until the end of Parts 1 and 2 (approximately 21 months)</time_frame>
        <posting_date>03/2025</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Fatal SAEs and SAEs Related to Study Drug During the First and Second Half of Part 3</title>
        <description>A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.</description>
        <time_frame>First and Second half (18 months each) of Part 3 (up to 3 years, beginning at Month 22)</time_frame>
        <posting_date>03/2025</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Seropositive Response for Each of the Four Dengue Serotypes in the Immunogenicity Subset</title>
        <description>Seropositive response is defined as a reciprocal neutralizing titer ≥ 10. The four DENV serotypes are DEN-1, DEN-2, DEN-3 and DEN-4.</description>
        <time_frame>Prevaccination on Day 1, post-first vaccination on Month 1, pre-vaccination on Month 3; post-second vaccination at Months 4, 9 and 15, and then annually (up to 3 years)</time_frame>
        <posting_date>03/2025</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Seropositive Response for Multiple Dengue Serotypes in the Immunogenicity Subset</title>
        <description>Seropositive response is defined as a reciprocal neutralizing titer ≥ 10. The four DENV serotypes are DEN-1, DEN-2, DEN-3 and DEN-4.</description>
        <time_frame>Prevaccination on Day 1, post-first vaccination on Month 1, pre-vaccination on Month 3; post-second vaccination at Months 4, 9 and 15, and then annually (up to 3 years)</time_frame>
        <posting_date>03/2025</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the Four Dengue Serotypes in the Immunogenicity Subset</title>
        <description>GMTs of neutralizing antibodies will be measured via microneutralization test 50% (MNT50). The four DENV serotypes are DEN-1, DEN-2, DEN-3 and DEN-4.</description>
        <time_frame>Prevaccination on Day 1, post-first vaccination on Month 1, pre-vaccination on Month 3; post-second vaccination at Months 4, 9 and 15, and then annually (up to 3 years)</time_frame>
        <posting_date>03/2025</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All-cause mortality and serious adverse events (SAEs): From Day 1 until the end of Parts 1 and 2 (approximately 21 months); First and Second half (18 months each) of Part 3 (up to 3 years); Other adverse events: Up to 28 days post second vaccination of each part</time_frame>
      <desc>The data for adverse events is not reported as this is primary results posting and the study is ongoing, reporting adverse events may cause unblinding, therefore, the data will be reported at the time of final results posting.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo (Part 1)</title>
          <description>Placebo-matching TDV, 0.5mL, subcutaneous (SC) injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study.</description>
        </group>
        <group group_id="E2">
          <title>Tetravalent Dengue Vaccine (TDV) 0.5 mL (Part 1)</title>
          <description>TDV, 0.5mL, subcutaneous (SC) injection on Day 1 (Month 0) and Day 90 (Month 3) in Part 1 of the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>TrialDisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

